Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leronlimab - CytoDyn

Drug Profile

Leronlimab - CytoDyn

Alternative Names: PA-14; PRO-140

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II/III HIV-1 infections
  • Phase II Graft-versus-host disease
  • Phase I/II Breast cancer
  • Preclinical Colorectal cancer; Prostate cancer

Most Recent Events

  • 14 Jan 2019 CytoDyn expects to launch leronlimab in HIV infections by 2020
  • 07 Jan 2019 CytoDyn expects to complete the filing of a Biological License Application (BLA) and Chemistry, Manufacturing and Controls submission in the first half of 2019 for HIV infections (Combination therapy) to the US FDA
  • 07 Jan 2019 Leronlimab is available for licensing as of 07 Jan 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top